Suven Life Sciences Ltd. Share Price, Chart, Info, Stock Analysis

Suven Life Sciences Ltd.
Snapshot View

View in App

Prices View details

82.30 -1.95 ▼-2.3%

30 July 2021, 04:00:00 P.M.
Volume: 17,590

Overview View Details

Financial Indicators Consolidated Standalone
Sector	Healthcare	Compare with Sector peers
Industry	Pharmaceuticals & Drugs	Compare with Industry peers
Website	http://www.suven.com
Market Cap	1,048.81 Cr.
Earnings per share (EPS)	-5.67	Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE)	-	Trailing Twelve Months Ending 2021-03
Industry PE	35.15	Trailing Twelve Months Ending 2021-03
Book Value / Share	5.58	Trailing Twelve Months Ending 2021-03
Price to Book Value	14.75	Calculated using Price: 82.40
Dividend Yield	0.00	Period Ending 2021-03
No. of Shares Subscribed	12.73 Cr.	127,282,478 Shares
FaceValue	1
Company Profile
Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995. Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia. Shares are listed at Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange(HSE). It has a state of the art R&D center recognized by Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India. Also, it has world class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Life Science Companies for New Chemical Entities (NCE's). Business Units C.R.A.M.S The company’s main thrust is in Contract Research and Manufacturing Services (C-R-A-M-S). Suven's ‘C-R-A-M-S’ is in existence since 1991 serving as many as 22 global Life Science and Fine Chemical Companies by developing and supplying cost effective Pharmaceutical and Agro Chemical Intermediates for New Chemical Entities (NCE's) meeting world standards of Quality, Speed and Respect for Environment. DDDSS Drug Discovery & Development Support Services (DDDSS) aims to provide Contract Drug Discovery & Development services in Medicinal chemistry, Process chemistry, Analytical chemistry, In-vitroScreening, DMPK, Brain Microdialysis, CV Safety, In-vivo Metabolic Disorders & CNS Pharmacology, Phase-I Bio-analysis and Discovery Toxicology. Suven Nishtaa Pharma Suven Nishtaa Pharma (Suven Nishtaa), a joint venture company of Suven Life Sciences, is a Pharmaceutical Formulations Contract Services provider. Suven Nishtaa, a 100% Export Oriented Unit, is engaged in providing end-to-end Drug Product Development services, viz. Products Advanced Intermediates IntermediatesActive Pharmaceutical Ingredients (APIs ) Stock Chemicals for Disposal Milestones 1989 Incorporation as Suven Pharmaceuticals Pvt. Ltd. 1990 Commenced Operations 1991 Expanded into Fine Chemical Intermediates 1992 Commenced export of Fine Chemical Intermediates 1994 Initiation of 'C-R-A-M-S' business model (Contract Research And Manufacturing Services) 1995 Went Public (IPO) 1996 First sale from 'C-R-A-M-S' 1997 ISO 9002 Certification 1999 Recognition as an Export House 1999 Acquired a Drug Unit at Hyderabad, converted into Research center and Pilot Plant 2001 New Suven Research Center (SRC) inaugurated at Hyderabad 2001 Recognition of SRC as in-house R & D unit by Department of Scientific & Industrial Research (DSIR), India 2001 Borregaard takes equity stake 2002 cGMP Lab at SRC commissioned 2003 Acquired assets of New Jersey, USA based Synthon Chiragenics Corporation 2003 Name changed to Suven Life Sciences Limited 2004 Gets ISO 14001:1996 certification for Unit - 1 (Suryapet) and Unit - 2 (Jeedimetla) 2005 Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan 2005 Suven Awarded Phase III Clinical study for Chronic Low Back pain. 2006 Suven receives National Accreditation Board for Testing and Calibration Laboratories (NABL) certification 2006 Suven and Lilly Establish Drug Discovery Collaboration 2006 Amalgamation of ASIAN CLINICAL TRIALS ( ACT) 2006 All the units got Certification for ISO 9001 , ISO 14001, OHSAS 18001 2007 Suven Unit III cGMP facility accepted by USFDA for manufacture of API's 2007 Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection 2007 Suven Life Sciences secures two Product Patents in Australia & New Zealand for their New Chemical Entities (NCEs) 2007 Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases. 2007 Suven obtains 1st Product Patent from US Patent office 2008 Suven obtains 2nd Product Patent from US Patent office 2008 Suven Establishes second CNS Drug Discovery Collaboration with Lilly 2008 Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region) 2008 Suven Life Sciences gets Two Product patents in Korea and Mexico 2008 Suven Life Sciences ACT Enters into an Alliance with VPSCRO 2008 Suven Life Sciences gets Two product patents for NCEs in South Africa and China 2008 Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride 2009 US FDA ACCEPTANCE to UNIT- I, Suryapet 2010 Suven Secures Two product patents in China and RussiaSuven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous SystemSuven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders.Suven Life Secures Three Australian Patents on NCEsSuven gets two patents from Japanese Patent Office for NCE's 2011 Suven's Unit-III receives US FDA AcceptanceSuven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the worldSuven Life Sciences bags ''Bio-Excellence Award at Bangalore India Bio 2011Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the worldSuven Life Sciences bags Pharmexcil's Gold ''Patent Award'' 2012 Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USASuven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and EurasiaSuven Life Sciences bags Pharmexcil's ''Platinum Patent Award''Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea. 2014 • Suven’s Pashamylaram’s Unit receives Us Fda Acceptance • Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export Performance Award” for Contract Research and Manufacturing. • Suven Life Sciences awarded Forbes Asia's ''Best Under A Billion'' Award 2015 • Suven Life Sciences bags Pharmexcil's ''Gold Patent Award'' • SUVN 502- Completed phase 1b clinical trial under US-IND; • SUVN-G3031- Completed SAD and MAD studies of phase 1 clinical trial under US-IND • SUVN-D4010 IND filed in USA • Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations • SUVN-D4010 for Cognition in Alzheimer’s disease commenced Phase 1 Clinical Trial in USA under US-IND126099 • Suven has created a wholly owned subsidiary, Suven, Inc., a Delaware Company in USA • Suven initiates Phase 2A trial of SUVN-502 in USA 2016 • SUVN-D4010 Phase 1 clinical trial completed successfully in USA. • Suven’s Pashamylaram unit successfully completed US FDA inspection 2017 • Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a nAChRs antagonist for MDD

Suven Life Sciences Ltd.

Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

Shares are listed at Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange(HSE). It has a state of the art R&D center recognized by Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India. Also, it has world class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Life Science Companies for New Chemical Entities (NCE's).

Business Units

C.R.A.M.S

The company’s main thrust is in Contract Research and Manufacturing Services (C-R-A-M-S). Suven's ‘C-R-A-M-S’ is in existence since 1991 serving as many as 22 global Life Science and Fine Chemical Companies by developing and supplying cost effective Pharmaceutical and Agro Chemical Intermediates for New Chemical Entities (NCE's) meeting world standards of Quality, Speed and Respect for Environment.

DDDSS

Drug Discovery & Development Support Services (DDDSS) aims to provide Contract Drug Discovery & Development services in Medicinal chemistry, Process chemistry, Analytical chemistry, In-vitroScreening, DMPK, Brain Microdialysis, CV Safety, In-vivo Metabolic Disorders & CNS Pharmacology, Phase-I Bio-analysis and Discovery Toxicology.

Suven Nishtaa Pharma

Suven Nishtaa Pharma (Suven Nishtaa), a joint venture company of Suven Life Sciences, is a Pharmaceutical Formulations Contract Services provider.

Suven Nishtaa, a 100% Export Oriented Unit, is engaged in providing end-to-end Drug Product Development services, viz.

Products

Advanced Intermediates
IntermediatesActive
Pharmaceutical Ingredients (APIs )
Stock Chemicals for Disposal

Milestones

1989 Incorporation as Suven Pharmaceuticals Pvt. Ltd.
1990 Commenced Operations
1991 Expanded into Fine Chemical Intermediates
1992 Commenced export of Fine Chemical Intermediates
1994 Initiation of 'C-R-A-M-S' business model (Contract Research And Manufacturing Services)
1995 Went Public (IPO)
1996 First sale from 'C-R-A-M-S'
1997 ISO 9002 Certification
1999 Recognition as an Export House
1999 Acquired a Drug Unit at Hyderabad, converted into Research center and Pilot Plant
2001 New Suven Research Center (SRC) inaugurated at Hyderabad
2001 Recognition of SRC as in-house R & D unit by Department of Scientific & Industrial Research (DSIR), India
2001 Borregaard takes equity stake
2002 cGMP Lab at SRC commissioned
2003 Acquired assets of New Jersey, USA based Synthon Chiragenics Corporation
2003 Name changed to Suven Life Sciences Limited
2004 Gets ISO 14001:1996 certification for Unit - 1 (Suryapet) and Unit - 2 (Jeedimetla)
2005 Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan
2005 Suven Awarded Phase III Clinical study for Chronic Low Back pain.
2006 Suven receives National Accreditation Board for Testing and Calibration Laboratories (NABL) certification
2006 Suven and Lilly Establish Drug Discovery Collaboration
2006 Amalgamation of ASIAN CLINICAL TRIALS ( ACT)
2006 All the units got Certification for ISO 9001 , ISO 14001, OHSAS 18001
2007 Suven Unit III cGMP facility accepted by USFDA for manufacture of API's
2007 Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection
2007 Suven Life Sciences secures two Product Patents in Australia & New Zealand for their New Chemical Entities (NCEs)
2007 Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases.
2007 Suven obtains 1st Product Patent from US Patent office
2008 Suven obtains 2nd Product Patent from US Patent office
2008 Suven Establishes second CNS Drug Discovery Collaboration with Lilly
2008 Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region)
2008 Suven Life Sciences gets Two Product patents in Korea and Mexico
2008 Suven Life Sciences ACT Enters into an Alliance with VPSCRO
2008 Suven Life Sciences gets Two product patents for NCEs in South Africa and China
2008 Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride
2009 US FDA ACCEPTANCE to UNIT- I, Suryapet
2010 Suven Secures Two product patents in China and RussiaSuven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous SystemSuven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders.Suven Life Secures Three Australian Patents on NCEsSuven gets two patents from Japanese Patent Office for NCE's
2011 Suven's Unit-III receives US FDA AcceptanceSuven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the worldSuven Life Sciences bags ''Bio-Excellence Award at Bangalore India Bio 2011Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the worldSuven Life Sciences bags Pharmexcil's Gold ''Patent Award''
2012 Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USASuven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and EurasiaSuven Life Sciences bags Pharmexcil's ''Platinum Patent Award''Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea.
2014
• Suven’s Pashamylaram’s Unit receives Us Fda Acceptance
• Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export Performance Award” for Contract Research and Manufacturing.
• Suven Life Sciences awarded Forbes Asia's ''Best Under A Billion'' Award
2015
• Suven Life Sciences bags Pharmexcil's ''Gold Patent Award''
• SUVN 502- Completed phase 1b clinical trial under US-IND;
• SUVN-G3031- Completed SAD and MAD studies of phase 1 clinical trial under US-IND
• SUVN-D4010 IND filed in USA
• Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations
• SUVN-D4010 for Cognition in Alzheimer’s disease commenced Phase 1 Clinical Trial in USA under US-IND126099
• Suven has created a wholly owned subsidiary, Suven, Inc., a Delaware Company in USA
• Suven initiates Phase 2A trial of SUVN-502 in USA
2016
• SUVN-D4010 Phase 1 clinical trial completed successfully in USA.
• Suven’s Pashamylaram unit successfully completed US FDA inspection
2017
• Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a nAChRs antagonist for MDD

Delivery View Details

Delivered Qty

Traded Qty

Performance View Details

1 Day		-2.31%
1 Week		-6.74%
1 Month		-6.42%
3 Month		-19.94%
6 Month		+16.33%
1 Year		+121.83%
2 Year		-63.01%
5 Year		-59.46%

Ratios View Details

	9 years	2006-03	2007-03	2015-03	2016-03	2017-03	2018-03	2019-03	2020-03	2021-03
Return on Equity (%)		7.46	11.76	32.91	12.50	13.81	17.25	-4.75	-49.27	-67.29
Return on Capital Employed (%)		7.59	10.74	37.93	15.43	18.19	26.01	0.40	-54.67	-60.09
Return on Assets (%)		4.58	7.12	22.38	8.87	9.97	12.84	-3.31	-27.07	-28.99

Particulars	7 years	2015-03 Rs. Cr.	2016-03 Rs. Cr.	2017-03 Rs. Cr.	2018-03 Rs. Cr.	2019-03 Rs. Cr.	2020-03 Rs. Cr.	2021-03 Rs. Cr.
Shh. Funds		559	595	667	767	239	143	108
Non Curr. Liab.		86	41	28	30	25	12	5
Curr. Liab.		127	211	208	226	157	120	110
Minority Int.
Equity & Liab.		773	846	903	1,023	421	275	222
Non Curr. Assets		291	319	322	350	22	116	26
Curr. Assets		477	528	581	674	398	160	197
Misc. Exp. not W/O		5
Total Assets		773	846	903	1,023	421	275	222

Profit Loss View Details

Consolidated
Standalone

Particulars	7 years	2015-03 Rs. Cr.	2016-03 Rs. Cr.	2017-03 Rs. Cr.	2018-03 Rs. Cr.	2019-03 Rs. Cr.	2020-03 Rs. Cr.	2021-03 Rs. Cr.
Net Sales		521	500	544	625	286	14	13
Other Income		9	20	21	23	27	14	8
Total Income		529	519	565	649	313	28	21
Total Expenditure		-361	-398	-414	-424	-297	-130	-93
PBIDT		168	121	150	225	16	-102	-72
Interest		-5	-6	-6	-5	-2	-1	-1
Depreciation		-12	-18	-21	-25	-14	-4	-4
Taxation		-43	-26	-36	-72	-24	12	5
Exceptional Items
PAT		109	72	87	124	-24	-94	-72

Cash Flow View Details

Consolidated
Standalone

Particulars	7 years	2015-03 Rs. Cr.	2016-03 Rs. Cr.	2017-03 Rs. Cr.	2018-03 Rs. Cr.	2019-03 Rs. Cr.	2020-03 Rs. Cr.	2021-03 Rs. Cr.
Cash Fr. Operatn.		143	68	109	70	-53	-135	-96
Cash Fr. Inv.		-110	-39	-311	-1	37	146	56
Cash Fr. Finan.		179	-68	-30	-52	5	3	35
Net Change		212	-39	-232	17	-11	14	-5
Cash & Cash Eqvt		279	241	9	26	0	15	9

Shareholding Pattern View Details

	9 Qtrs	2019-06 (%)	2019-09 (%)	2019-12 (%)	2020-03 (%)	2020-06 (%)	2020-09 (%)	2020-12 (%)	2021-03 (%)	2021-06 (%)
Promoter		60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00
Public		40.00	40.00	40.00	40.00	40.00	40.00	40.00	40.00	40.00
Depository Receipts		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Promoter Holding Pledge (%)		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Announcements View Details

Tue, 20 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021

No.of Investor complaints pending at the beginning of the quarter	No.of Investor complaints received during the quarter	No.of Investor complaints disposed of during the quarter	No.of Investor complaints unresolved at the end of the quarter
0	10	10	0

Name of the Signatory	:-	Shrenik Soni
Designation	:-	Company Secretary and Compliance Officer

Fri, 16 Jul 2021
Shareholding for the Period Ended June 30 2021
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Tue, 13 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated 12th July 2021 regarding Notice of the 32nd Annual General Meeting of the Company and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed the copies of the newspaper advertisements regarding Notice of the 32nd Annual General Meeting of the Company Book Closure and E-Voting Information as appeared on 13th July 2021 in Nava Telangana (Telugu) and Business Standard.

The above information will also be hosted on the website of the Company at: http://www.suven.com/agm.aspx.

Technical Scans View Details

Fri, 30 Jul 2021

Stock Underperforming Benchmark Index in both 1 Week and 3 Month

Stock Underperforming Sectoral Index in both 1 Week and 3 Month

Strongly Underperforming Benchmark index

Strongly Underperforming Sectoral index

Close Crossing Lower Bollinger Band From Above

Related Stocks View Details

Stock Name	Market Cap(Rs. Cr.)	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	185,708.53	774.00	+10.1%
Divi's Laboratories Ltd.	129,702.64	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	78,400.54	4,712.70	+0.9%
Cipla Ltd.	74,235.31	920.30	+4.3%
Cadila Healthcare Ltd.	59,986.20	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	57,873.32	4,025.00	-0.3%
Aurobindo Pharma Ltd.	53,701.27	916.50	+0.9%

Market Cap(Rs. Cr.)
Sun Pharmaceutical Industries Ltd.	185,708.53	774.00 +10.1%
Divi's Laboratories Ltd.	129,702.64	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd.	78,400.54	4,712.70 +0.9%
Cipla Ltd.	74,235.31	920.30 +4.3%
Cadila Healthcare Ltd.	59,986.20	585.95 +2.5%
Apollo Hospitals Enterprise Ltd.	57,873.32	4,025.00 -0.3%
Aurobindo Pharma Ltd.	53,701.27	916.50 +0.9%

Stock Name	Statement	TTM Ending	Price Earning Ratio(TTM)	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	Consolidated	2021-03	63.95	774.00	+10.1%
Divi's Laboratories Ltd.	Consolidated	2021-03	65.36	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	Consolidated	2021-06	45.13	4,712.70	+0.9%
Cipla Ltd.	Consolidated	2021-03	30.87	920.30	+4.3%
Cadila Healthcare Ltd.	Consolidated	2021-03	28.12	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	Consolidated	2021-03	384.90	4,025.00	-0.3%
Aurobindo Pharma Ltd.	Consolidated	2021-03	10.07	916.50	+0.9%

Price Earning Ratio(TTM)
Sun Pharmaceutical Industries Ltd. 2021-03 \| Consolidated	63.95	774.00 +10.1%
Divi's Laboratories Ltd. 2021-03 \| Consolidated	65.36	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 2021-06 \| Consolidated	45.13	4,712.70 +0.9%
Cipla Ltd. 2021-03 \| Consolidated	30.87	920.30 +4.3%
Cadila Healthcare Ltd. 2021-03 \| Consolidated	28.12	585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 2021-03 \| Consolidated	384.90	4,025.00 -0.3%
Aurobindo Pharma Ltd. 2021-03 \| Consolidated	10.07	916.50 +0.9%

Stock Name	Statement	TTM Ending	Price To Book Value(TTM)	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	Consolidated	2021-03	4.00	774.00	+10.1%
Divi's Laboratories Ltd.	Consolidated	2021-03	13.95	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	Consolidated	2021-06	4.39	4,712.70	+0.9%
Cipla Ltd.	Consolidated	2021-03	4.05	920.30	+4.3%
Cadila Healthcare Ltd.	Consolidated	2021-03	4.62	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	Consolidated	2021-03	12.60	4,025.00	-0.3%
Aurobindo Pharma Ltd.	Consolidated	2021-03	2.45	916.50	+0.9%

Price To Book Value(TTM)
Sun Pharmaceutical Industries Ltd. 2021-03 \| Consolidated	4.00	774.00 +10.1%
Divi's Laboratories Ltd. 2021-03 \| Consolidated	13.95	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 2021-06 \| Consolidated	4.39	4,712.70 +0.9%
Cipla Ltd. 2021-03 \| Consolidated	4.05	920.30 +4.3%
Cadila Healthcare Ltd. 2021-03 \| Consolidated	4.62	585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 2021-03 \| Consolidated	12.60	4,025.00 -0.3%
Aurobindo Pharma Ltd. 2021-03 \| Consolidated	2.45	916.50 +0.9%

Stock Name	Statement	Year Ending	Debt Equity Ratio	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	Consolidated	2020-03	0.18	774.00	+10.1%
Divi's Laboratories Ltd.	Consolidated	2020-03	0.00	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	Consolidated	2021-03	0.17	4,712.70	+0.9%
Cipla Ltd.	Consolidated	2020-03	0.18	920.30	+4.3%
Cadila Healthcare Ltd.	Consolidated	2021-03	0.35	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	Consolidated	2020-03	1.08	4,025.00	-0.3%
Aurobindo Pharma Ltd.	Consolidated	2020-03	0.33	916.50	+0.9%

Debt Equity Ratio
Sun Pharmaceutical Industries Ltd. 2020-03 \| Consolidated	0.18	774.00 +10.1%
Divi's Laboratories Ltd. 2020-03 \| Consolidated	0.00	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 2021-03 \| Consolidated	0.17	4,712.70 +0.9%
Cipla Ltd. 2020-03 \| Consolidated	0.18	920.30 +4.3%
Cadila Healthcare Ltd. 2021-03 \| Consolidated	0.35	585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 2020-03 \| Consolidated	1.08	4,025.00 -0.3%
Aurobindo Pharma Ltd. 2020-03 \| Consolidated	0.33	916.50 +0.9%

Stock Name	Statement	Year Ending	Return On Equity(%)	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	Consolidated	2020-03	9.66	774.00	+10.1%
Divi's Laboratories Ltd.	Consolidated	2020-03	19.30	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	Consolidated	2021-03	11.53	4,712.70	+0.9%
Cipla Ltd.	Consolidated	2020-03	10.09	920.30	+4.3%
Cadila Healthcare Ltd.	Consolidated	2021-03	18.30	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	Consolidated	2020-03	13.08	4,025.00	-0.3%
Aurobindo Pharma Ltd.	Consolidated	2020-03	18.53	916.50	+0.9%

Return On Equity(%)
Sun Pharmaceutical Industries Ltd. 2020-03 \| Consolidated	9.66	774.00 +10.1%
Divi's Laboratories Ltd. 2020-03 \| Consolidated	19.30	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 2021-03 \| Consolidated	11.53	4,712.70 +0.9%
Cipla Ltd. 2020-03 \| Consolidated	10.09	920.30 +4.3%
Cadila Healthcare Ltd. 2021-03 \| Consolidated	18.30	585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 2020-03 \| Consolidated	13.08	4,025.00 -0.3%
Aurobindo Pharma Ltd. 2020-03 \| Consolidated	18.53	916.50 +0.9%

Stock Name	Statement	Year Ending	Return On Capital Employed(%)	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	Consolidated	2020-03	10.07	774.00	+10.1%
Divi's Laboratories Ltd.	Consolidated	2020-03	25.36	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	Consolidated	2021-03	15.24	4,712.70	+0.9%
Cipla Ltd.	Consolidated	2020-03	12.53	920.30	+4.3%
Cadila Healthcare Ltd.	Consolidated	2021-03	13.65	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	Consolidated	2020-03	17.13	4,025.00	-0.3%
Aurobindo Pharma Ltd.	Consolidated	2020-03	18.80	916.50	+0.9%

Return On Capital Employed(%)
Sun Pharmaceutical Industries Ltd. 2020-03 \| Consolidated	10.07	774.00 +10.1%
Divi's Laboratories Ltd. 2020-03 \| Consolidated	25.36	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 2021-03 \| Consolidated	15.24	4,712.70 +0.9%
Cipla Ltd. 2020-03 \| Consolidated	12.53	920.30 +4.3%
Cadila Healthcare Ltd. 2021-03 \| Consolidated	13.65	585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 2020-03 \| Consolidated	17.13	4,025.00 -0.3%
Aurobindo Pharma Ltd. 2020-03 \| Consolidated	18.80	916.50 +0.9%

Stock Name	Statement	Year Ending	Net Sales(Rs. Cr.)	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	Consolidated	2020-03	32,837.50	774.00	+10.1%
Divi's Laboratories Ltd.	Consolidated	2020-03	5,394.42	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	Consolidated	2021-03	19,047.50	4,712.70	+0.9%
Cipla Ltd.	Consolidated	2020-03	17,131.99	920.30	+4.3%
Cadila Healthcare Ltd.	Consolidated	2021-03	15,102.20	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	Consolidated	2020-03	11,246.80	4,025.00	-0.3%
Aurobindo Pharma Ltd.	Consolidated	2020-03	23,098.51	916.50	+0.9%

Net Sales(Rs. Cr.)
Sun Pharmaceutical Industries Ltd. 2020-03 \| Consolidated	32,837.50	774.00 +10.1%
Divi's Laboratories Ltd. 2020-03 \| Consolidated	5,394.42	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 2021-03 \| Consolidated	19,047.50	4,712.70 +0.9%
Cipla Ltd. 2020-03 \| Consolidated	17,131.99	920.30 +4.3%
Cadila Healthcare Ltd. 2021-03 \| Consolidated	15,102.20	585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 2020-03 \| Consolidated	11,246.80	4,025.00 -0.3%
Aurobindo Pharma Ltd. 2020-03 \| Consolidated	23,098.51	916.50 +0.9%

Stock Name	Statement	Year Ending	Profit After Tax(Rs. Cr.)	LTP	Chg %
Sun Pharmaceutical Industries Ltd.	Consolidated	2020-03	4,186.79	774.00	+10.1%
Divi's Laboratories Ltd.	Consolidated	2020-03	1,376.54	4,885.80	+0.8%
Dr. Reddy's Laboratories Ltd.	Consolidated	2021-03	1,903.60	4,712.70	+0.9%
Cipla Ltd.	Consolidated	2020-03	1,546.98	920.30	+4.3%
Cadila Healthcare Ltd.	Consolidated	2021-03	2,137.60	585.95	+2.5%
Apollo Hospitals Enterprise Ltd.	Consolidated	2020-03	434.90	4,025.00	-0.3%
Aurobindo Pharma Ltd.	Consolidated	2020-03	2,844.69	916.50	+0.9%

Profit After Tax(Rs. Cr.)
Sun Pharmaceutical Industries Ltd. 2020-03 \| Consolidated	4,186.79	774.00 +10.1%
Divi's Laboratories Ltd. 2020-03 \| Consolidated	1,376.54	4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 2021-03 \| Consolidated	1,903.60	4,712.70 +0.9%
Cipla Ltd. 2020-03 \| Consolidated	1,546.98	920.30 +4.3%
Cadila Healthcare Ltd. 2021-03 \| Consolidated	2,137.60	585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 2020-03 \| Consolidated	434.90	4,025.00 -0.3%
Aurobindo Pharma Ltd. 2020-03 \| Consolidated	2,844.69	916.50 +0.9%

Suven Life Sciences Ltd. Snapshot View